News List

Takeda announced the Phase 3 SHP643 to evaluate the safety and pharmacokinetics of Takhzyro (lanadelumab)
2022-05-13

Takeda announced the Phase 3 SHP643 to evaluate the safety and pharmacokinetics of Takhzyro (lanadel

Bristol-Myers Squibb (BMS) presented 2-year data from the POETYK PSO long-term extension trial of the novel oral TYK2 inhibitor deucravacitinib
2022-05-13

Recently, Bristol-Myers Squibb (BMS) presented 2-year data from the POETYK PSO long-term extension t

AbbVie's oral JAK inhibitor Rinvoq (upatinib) approved by NMPA
2022-03-11

AbbVie recently announced that China’s National Medical Products Administration (NMPA) has approved

Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)
2022-02-11

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (

Novartis' asciminib bests Pfizer's Bosulif in phase 3 leukemia trial
2021-11-02

Novartis’ asciminib hasoutperformedPfizer’s Bosulif in a phase 3 chronic myeloid leukemia (CML) stud

Hengrui announces new drug SHR7280
2021-10-16

On October 11, 2021, Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that SHR0302, for the treat

Novartis secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasis
2021-08-23

August 17, 2021 – Novartis today announced that the China National Medical Products Administration (

Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU
2021-07-27

Berlin, Germany, July 21, 2021– The European Commission has granted marketing authorization in the E